The pharmacodynamics of PD-1/PD-L1 inhibitors determined that their action on T cells is effective against tumors after activating the immune response of T cells to tumor cells, while an excessive autoimmune response may occur when T cells act on normal cells, resulting in irAEs56. This evidence concerns the gene PDCD1 and neoplasm.